Form 4: Karyopharm Therapeutics CEO Richard Paulson Sells Shares to Cover Tax Obligations

Richard Paulson, CEO of Karyopharm Therapeutics, sold 245 shares of common stock to cover withholding tax liabilities.

Summary

• Richard Paulson, the President and CEO of Karyopharm Therapeutics Inc., sold 245 shares of common stock on April 4, 2025.
• The sale was executed at a weighted average price of $3.74 per share, with individual transactions ranging from $3.74 to $3.86.
• The transaction was conducted under a pre-arranged automatic sale plan adopted on June 10, 2021, to cover withholding tax obligations arising from the vesting of restricted stock units.
• Following the transaction, Paulson directly owns 82,739 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 6

Explanation: The document is neutral. It simply reports a stock sale by an executive to cover tax obligations under a pre-arranged plan. It doesn't indicate any positive or negative sentiment about the company's prospects.

Industry Context

This is a routine Form 4 filing, indicating insider transactions. It is common for executives to sell shares to cover tax obligations, especially after vesting of stock options or restricted stock units. The existence of a pre-arranged trading plan suggests the sale was not based on any inside information.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although the sale was pre-planned and for tax purposes.

Key Dates

Keywords

Karyopharm Therapeutics, Richard Paulson, stock sale, Form 4, insider trading, tax liabilities, automatic sale plan, KPTI